HomeMarket NewsBiotech Stocks Take a Tumble Over Weight-Loss Study Disappointment

Biotech Stocks Take a Tumble Over Weight-Loss Study Disappointment

Actionable Trade Ideas

always free

Obesity Death Risk

wildpixel/iStock via Getty Images

Biotech stocks Clearmind (NASDAQ:CMND) and SciSparc (NASDAQ:SPRC) took a nosedive of approximately 7% during early trading on Tuesday following Clearmind’s disclosure of results from a preclinical study involving its drug MEAI in combination with SciSparc’s PEA for potential weight loss and metabolic disorder treatment.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.